Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial

Next Previous
X
Search
Trial Profile

ONgoing Telmisartan Alone or in combination with Ramipril Global Endpoint Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telmisartan (Primary) ; Ramipril
  • Indications Angina pectoris; Cardiovascular disorders; Heart failure; Hypertension; Intermittent claudication; Left ventricular hypertrophy; Myocardial infarction; Stroke; Unstable angina pectoris
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ONTARGET
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 28 Mar 2019 Results of pooled post hoc analysis from ONTARGET/TRANSCEND studies assessing cardiovascular outcomes and achieved blood pressure published in the European Heart Journal.
    • 24 Dec 2018 Results assessing resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals from ONTARGET and TRANSCEND trials, published in the European Heart Journal.
    • 01 Feb 2013 Results published in the Journal of Hypertension.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top